Multicenter phase 2 study of BVAC-C plus durvalumab for recurrent or metastatic cervical cancer

Immune checkpoint inhibitors show limited efficacy in previously treaten recurrent or metastatic cervical cancer (RMCC). BVAC-C is an autologous B cell-based and monocyte-based therapeutic vaccine targeting HPV 16/18 E6 and E7 oncoproteins. A multicenter phase 2 trial in South Korea evaluated the combination of BVAC-C and durvalumab for HPV18/18-positive rmCC after progression on platinum-based chemotherapy. Thirty patients received treatment; 29 were evaluable for efficacy. The objective response rate (ORR) was 37.9% (six complete responses and five partial responses) and the disease control rate was 62.1%. The 6-month progression-free survival (PFS) rate was 51.7% and median PFS was 8.7 months (95% CI 4.0-24.3). Patients with a treatment-free interval longer than 6 months achieved significantly higher ORR (52.9% versus 16.7%; p=0.047). The median duration of response was 20 months, and complete responders showed sustained remission beyond 18 months, raising the possibility of functional cure in a subset of patients. The authors conclude that second-line BVAC-C plus durvalumab showed encouraging antitumor activity with a manageable safety profile among patients with rmCC.